Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Zug, Switzerland, May 4, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the first quarter of 2017 on Thursday, May 11, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3374 (International), and enter passcode 5733572. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
